<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vancomycin hypersensitivity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vancomycin hypersensitivity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vancomycin hypersensitivity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            N Franklin Adkinson, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         causes several different types of hypersensitivity reactions, ranging from localized skin reactions to generalized cardiovascular collapse. The most common adverse reaction is vancomycin infusion reaction (VIR). VIR is a rate-dependent infusion reaction, not a true allergic reaction.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         hypersensitivity will be reviewed here. Other antibiotics that commonly cause hypersensitivity reactions include the beta-lactam antibiotics and sulfonamides, and hypersensitivity reaction to these drugs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1904250082">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The terms "red man syndrome" or "red neck syndrome" have commonly been used to describe
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         infusion reaction (VIR). Another term that is variably used is vancomycin flushing syndrome or reactions. This terminology originated from the dramatic erythema that develops in some patients in response to infusion of vancomycin, but the terms could be misconstrued as insulting to specific groups of people in the United States, and the emphasis on flushing, which is a prominent feature but not the only one, may lead to the reaction being missed in patients with darker skin [
         <a href="#rid1">
          1,2
         </a>
         ]. Thus, the term "vancomycin infusion reaction" is preferred.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          VANCOMYCIN INFUSION REACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is "vancomycin infusion reaction (VIR)," previously known as "red man syndrome," although we will avoid further use of this term for the reasons outlined previously. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4297907">
         <span class="h2">
          Route of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         VIR occurs principally with parenteral administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . Rarely, VIR has been caused by topical administration of vancomycin powder [
         <a href="#rid3">
          3
         </a>
         ]. In contrast, oral administration of vancomycin in subjects with
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         infections does not usually result in systemic absorption [
         <a href="#rid4">
          4
         </a>
         ]. However, for some patients, especially those with impaired kidney function or other abnormalities, oral administration can lead to detectable serum levels of the medication, and VIR to oral vancomycin may be possible [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         VIR may develop with the first administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . It is characterized by flushing, erythema, and pruritus, usually affecting the upper body, neck, and face more than the lower body. Pains and muscle spasms in the back and chest, dyspnea, and hypotension may also occur [
         <a href="#rid6">
          6,7
         </a>
         ]. Otherwise unexplained hypotension has been reported [
         <a href="#rid8">
          8,9
         </a>
         ]. In a retrospective review of multiinstitutional electronic medical records, amongst 3165 recipients of vancomycin, 491 experienced adverse drug reactions, of which 134 were immediate hypersensitivity reactions [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         VIR is rarely life threatening, although severe cardiovascular toxicity and even cardiac arrest can occur [
         <a href="#rid8">
          8,11
         </a>
         ]. Immunoglobulin E (IgE) mediated anaphylaxis can present with symptoms similar or identical to those of severe VIR, and clinicians should be mindful of this alternative diagnosis. Unlike VIR, an IgE-mediated reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         does not occur with initial administration but instead requires sensitization to develop from a previous course of vancomycin. (See
         <a class="local">
          'IgE-mediated anaphylaxis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Mechanism
         </span>
         <span class="headingEndMark">
          —
         </span>
         VIR is an idiopathic reaction, which is not thought to involve drug-specific antibodies. VIR is a form of pseudoallergic drug reaction, which is an adverse drug reaction with signs and symptoms that mimic immunologic drug allergies but in which IgE-mediated immunologic mechanisms have not been demonstrated.
        </p>
        <p>
         Studies in animals indicate that
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         directly activates mast cells, resulting in release of vasoactive mediators, such as histamine [
         <a href="#rid12">
          12,13
         </a>
         ]. A mast cell specific G-protein coupled receptor in mice and its human orthologue, MRGPRX2, have been identified as mediating pseudoallergic mast cell activation, as elicited by candidate agents, including
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ]. In this study, vancomycin was not evaluated, although vancomycin was shown to activate human mast cells through MRGPRX2 in an in vitro study [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3981.html" rel="external">
          "Mast cells: Surface receptors and signal transduction", section on 'MRGPRX2'
         </a>
         .)
        </p>
        <p>
         In several human studies, the degree of elevation in serum histamine was related to the clinical severity of VIR [
         <a href="#rid16">
          16-18
         </a>
         ]. However, in other studies, increased serum histamine concentrations did not predict VIR, and VIR occurred without detectable elevations in plasma histamine [
         <a href="#rid19">
          19
         </a>
         ], suggesting either that other mediators may be involved or that plasma histamine is not a sufficiently sensitive marker for mast cell activation localized to the skin.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Relationship to infusion rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         VIR is usually a rate-related infusion reaction, as illustrated by the following observations [
         <a href="#rid16">
          16,20-22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 10 healthy presurgical patients received rapid infusions of 1 gram of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         over 10 minutes [
         <a href="#rid20">
          20
         </a>
         ]. All developed VIR, seven had severe cutaneous reactions, and five had a reduction in blood pressure of 20 percent or more, necessitating discontinuation of the infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report of 10 adult male volunteers, the incidence and severity of VIR following the infusion of 1 gram of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         over either one or two hours was compared [
         <a href="#rid16">
          16
         </a>
         ]. Eight subjects developed VIR (two severe, three moderate, and three mild) with the one-hour infusion compared with three (all mild) with the two-hour infusion. However, two studies with a total of 62 hospitalized patients with serious infections found a much lower risk of VIR (less than 10 percent) following 1 gram infused over one hour [
         <a href="#rid17">
          17,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Predisposing medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mast cells are more easily activated when
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is given in combination with certain other medications. The combination of vancomycin and opioids (eg,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ) enhances dose- or rate-related mast cell degranulation [
         <a href="#rid23">
          23
         </a>
         ]. Adverse reactions can occur following administration of vancomycin in patients being treated with an opioid or following the administration of opioids in patients being treated with vancomycin [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Similar interactions can occur between
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and radiocontrast dye, some muscle relaxants used in general anesthesia, and any other agents that potentiate mast cell degranulation  (
         <a class="graphic graphic_table graphicRef74197" href="/z/d/graphic/74197.html" rel="external">
          table 1
         </a>
         ). Thus, when possible, these agents should
         <strong>
          not
         </strong>
         be administered simultaneously or in close approximation with vancomycin.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Prevention of initial reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of VIR involves the use of slower infusion rates and, in some situations, premedication.
        </p>
        <p class="headingAnchor" id="H1906720523">
         <span class="h3">
          Slower infusion rates
         </span>
         <span class="headingEndMark">
          —
         </span>
         To avoid VIR,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         should be infused at a rate no higher than 10 mg/minute or, for a 1 gram dose, over a minimum of 100 minutes (whichever results in a slower infusion) [
         <a href="#rid22">
          22
         </a>
         ]. We advise even slower rates of infusion for patients who are also receiving opioids or other medications that predispose to mast cell activation  (
         <a class="graphic graphic_table graphicRef74197" href="/z/d/graphic/74197.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Predisposing medications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2695560096">
         <span class="h3">
          Premedication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric premedication to prevent VIR is not usually necessary for patients who are receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for the first time at rates of infusion ≤10 mg/min. We generally do not administer premedication for doses ≤500 mg given over one hour or doses of 500 mg to 1 gram given over two hours.
        </p>
        <p>
         In contrast, empiric premedication with antihistamines
         <strong>
          is
         </strong>
         commonly employed if more rapid infusions of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         are required in emergency or presurgical settings. We administer premedication for patients receiving vancomycin at high rates of infusion (more than 10 mg/minute or 1 gram over one hour). Oral antihistamines are preferred when possible. Although H1 antihistamines may be sufficient for mildly increased infusion rates, we suggest administration of both an H1 and H2 antihistamine to minimize the likelihood of a reaction if significantly faster rates are used (eg, 1 gram over 10 minutes).
        </p>
        <p>
         The efficacy of pretreatment with antihistamines in reducing the incidence and severity of VIR was evaluated in the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial of 33 patients found that pretreatment with
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally) completely prevented VIR in a group of patients receiving 1 gram of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         over 60 minutes [
         <a href="#rid17">
          17
         </a>
         ]. Reactions occurred in 47 percent of the placebo group compared with none in the diphenhydramine group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of very rapid infusions (1 gram over 10 minutes) in 30 presurgical patients, oral premedication with both H1 and H2 antihistamines was given [
         <a href="#rid20">
          20
         </a>
         ]. Subjects received oral
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (≤1 mg per kg) plus oral
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         (≤4 mg per kg) one hour before infusion. The incidence and severity of VIR were significantly lower in the antihistamine-treated group, although one antihistamine-treated patient had intolerable itching and could not complete the infusion. Hypotension did not occur in the antihistamine group but developed in 50 percent of patients in the placebo group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The same investigators performed another randomized trial in 40 patients using the same medications, doses, and setting as in the previous trial (ie, 1 gram over 10 minutes), although the antihistamine premedications (
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         and
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         ) were administered intravenously [
         <a href="#rid25">
          25
         </a>
         ]. Patients treated with an antihistamine had significantly lower rates of hypotension (11 versus 63 percent) and cutaneous findings (63 versus 100 percent). Itching was severe enough in two antihistamine-treated patients to necessitate discontinuation of the infusion.
        </p>
        <p>
        </p>
        <p>
         Based upon these limited data, premedication with H1 alone may be sufficient to prevent VIR following mildly increased rates of infusion, although even the combination of H1 and H2 antihistamines did not completely prevent VIR following very rapid infusions (1 gram over 10 minutes) of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . Oral and intravenous antihistamine premedications appear to be similarly efficacious.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal management of VIR has not been evaluated in randomized trials. The approach outlined herein is based upon the author's clinical experience.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For mild reactions (eg, flushing that is not bothersome to the patient), symptoms typically resolve in minutes, and antihistamines are usually not necessary. We usually restart the infusion at one-half of the previous rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For moderate reactions (eg, the patient is uncomfortable due to flushing or pruritus but hemodynamically stable and not experiencing chest pain or muscle spasm), we typically interrupt the infusion and treat with
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally or intravenously) and
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         (20 mg intravenously). Symptoms usually subside promptly. The infusion can then be restarted at one-half the original rate or 10 mg/minute, whichever is slower.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe reactions (eg, involving muscle spasm, chest pain, or hypotension), we stop the infusion and treat with
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg intravenously) as well as
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         (20 mg intravenously) and, if hypotension is present, intravenous fluids. Once symptoms have resolved, the infusion can be restarted and given over four or more hours. For administration of future doses, we suggest repeat premedication with antihistamines before each dose and infusion over four hours, as well as continuous hemodynamic monitoring during infusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It may be difficult or impossible to distinguish severe VIR from anaphylaxis. Flushing and hypotension are features of both reactions. Hives, laryngeal edema, and wheezing are suggestive of anaphylaxis, and patients with these signs and symptoms should be treated with intramuscular
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , in addition to the measures above. Overviews of the treatment of anaphylaxis in adults and in children (with specific medication doses) are provided in the tables  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ). Infusions must
         <strong>
          not
         </strong>
         be restarted if anaphylaxis is suspected, because slowing the rate and administering premedications will not prevent IgE-mediated anaphylaxis. (See
         <a class="local">
          'IgE-mediated anaphylaxis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Following VIR of any severity, the patient's medication list should be reviewed to determine if other predisposing medications (eg, opioids)  (
         <a class="graphic graphic_table graphicRef74197" href="/z/d/graphic/74197.html" rel="external">
          table 1
         </a>
         ) can be identified and discontinued before restarting the infusion.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Recurrent reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some individuals experience recurrent and persistent symptoms despite premedication and slower infusion rates [
         <a href="#rid17">
          17,24,26
         </a>
         ]. These individuals may have mast cells and/or basophils that are easily activated. Patients with mast cell disorders are particularly prone to VIR with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">
          "Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis", section on 'Triggers for mediator release'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">
          "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Desensitization can be attempted if there is no equally effective alternative antibiotic and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is absolutely required. (See
         <a class="local">
          'Desensitization'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          IgE-MEDIATED ANAPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaphylaxis is an immunologically mediated reaction involving drug-specific IgE antibodies. Anaphylaxis in response to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         administration is believed to be rare, although reactions involving angioedema, respiratory distress, and bronchospasm with demonstrable drug-specific IgE have been described [
         <a href="#rid26">
          26-28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p>
         Patients with anaphylactic reactions to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         often have a history of multiple prior exposures. Anaphylaxis does not occur on the first administration of the medication, because prior exposure to the drug is necessary to form drug-specific IgE antibodies.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The symptoms of anaphylaxis include (but are not limited to) urticaria, angioedema, generalized pruritus, tachycardia, hypotension, nausea and vomiting, lightheadedness, and hypotension  (
         <a class="graphic graphic_table graphicRef66333" href="/z/d/graphic/66333.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Although severe
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         infusion reactions (VIR) and anaphylaxis can present with similar signs and symptoms, wheezing and respiratory distress are more common in anaphylaxis, whereas VIR more often involves chest pains causing a sensation of chest tightness. Angioedema is usually seen in anaphylaxis only. However, it may not be possible to distinguish anaphylaxis from severe VIR based upon clinical presentation. The patient should be assumed to have anaphylaxis in such cases and managed accordingly.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Acute management
         </span>
         <span class="headingEndMark">
          —
         </span>
         If anaphylaxis is suspected, the
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         infusion should be stopped immediately, and the patient should be treated with intramuscular
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         . Overviews of the treatment of anaphylaxis in adults and in children (with specific medication doses) are provided in the tables  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ). A more detailed discussion of the treatment of anaphylaxis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Differentiating between anaphylaxis and severe VIR is usually based upon clinical signs and symptoms. Unfortunately, serum and skin tests cannot reliably discriminate between these two reactions. In addition,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         skin testing has not been validated, and the positive and negative predictive values are unknown.
        </p>
        <p class="headingAnchor" id="H9035576">
         <span class="h3">
          Serum tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum tryptase levels have been studied in severe reactions to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid29">
          29-35
         </a>
         ]. Tryptase is stored preformed within mast cell granules and released during mast cell degranulation. Elevations in these mast cell-derived mediators are variably found in IgE-mediated anaphylaxis, although normal levels do not exclude anaphylaxis. (See
         <a class="medical medical_review" href="/z/d/html/389.html" rel="external">
          "Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Tryptase'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2322927">
         <span class="h3">
          Skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin testing with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         has not been validated, and the positive and negative predictive value of the results are not known. However, isolated case reports described reactions that were highly suggestive of IgE-mediated drug allergy in which skin test results were positive [
         <a href="#rid36">
          36
         </a>
         ]. As an example, one patient developed generalized urticaria and respiratory distress after several doses of vancomycin [
         <a href="#rid27">
          27
         </a>
         ]. Intradermal skin tests were positive at 0.1 mcg/mL, whereas control subjects had positive results only at much higher concentrations (&gt;10 mcg/mL). The patient was desensitized over 13 days, after which repeat skin testing was negative, which is a clinical marker of successful desensitization in IgE-mediated reactions. Another case report also documented positive skin tests results that converted to negative following desensitization [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="local">
          'Desensitization'
         </a>
         below.)
        </p>
        <p>
         These reports suggest that skin testing with appropriate
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations may reflect clinical reactivity and provide supportive evidence for the clinical diagnosis of anaphylaxis. A positive skin test at concentrations of 1 mcg/mL or lower is strongly suggestive of drug allergy in a patient with a reaction that had features of allergy.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Use of alternate medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other antimicrobial agents should be considered for patients who have experienced very severe symptoms in response to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . Some patients receive vancomycin because of a reported history of allergy to penicillins, yet penicillin may be a superior antibiotic for certain infections, such as native valve endocarditis due to methicillin-sensitive
         <em>
          Staphylococcus aureus
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         Patients are sometimes labeled as penicillin allergic based on a vague past history or may have lost the allergy over time. Presurgical evaluation by an allergy specialist to confirm or exclude penicillin allergy should be arranged whenever possible. Several studies have demonstrated the value of avoiding
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for surgical prophylaxis in patients with a self-reported history of penicillin allergy [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions"
         </a>
         .)
        </p>
        <p>
         There are limited antibiotic options for certain infections, however, such as methicillin-resistant
         <em>
          S. aureus
         </em>
         , coagulase-negative staphylococci, and ampicillin-resistant enterococci.
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          Daptomycin
         </a>
         has been used successfully in a patient intolerant to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ]. Alternative agents are discussed in detail in specific topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3154.html" rel="external">
          "Infection due to coagulase-negative staphylococci: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">
          "Treatment of enterococcal infections"
         </a>
         .)
        </p>
        <p>
         Glycopeptide antibiotics structurally similar to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         include
         <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">
          telavancin
         </a>
         ,
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         , and
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="local">
          'Use of related drugs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desensitization is a procedure that alters the immune activation by the drug and results in
         <strong>
          temporary
         </strong>
         tolerance, allowing the patient with a drug hypersensitivity reaction to receive an uninterrupted course of the medication safely. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2323286">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Readministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         to a patient with a past
         <strong>
          severe VIR
         </strong>
         or
         <strong>
          possible anaphylaxis
         </strong>
         may need to be considered when no other antimicrobial of equivalent efficacy is available. Vancomycin desensitization is appropriate for both suspected IgE-mediated reactions (preferably confirmed by skin testing) and may be clinically useful for severe VIR that was refractory to the measures outlined above [
         <a href="#rid24">
          24,27,37,43,44
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desensitization, or any form of reexposure, is
         <strong>
          contraindicated
         </strong>
         in patients with the following types of past reactions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exfoliative skin reactions – Reactions involving blistering, peeling, or sloughing of the skin, such as Stevens-Johnson syndrome and toxic epidermal necrolysis (see
         <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug reaction with eosinophilia and systemic symptoms (DRESS), also called the drug-induced hypersensitivity syndrome [
         <a href="#rid45">
          45,46
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">
          "Drug hypersensitivity: Classification and clinical features"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Desensitization is generally not performed in patients with past drug fever, hematologic or renal hypersensitivity reactions, phlebitis, or linear immunoglobulin A (IgA) bullous dermatosis. (See
         <a class="local">
          'Other forms of hypersensitivity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2323333">
         <span class="h3">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with an allergy specialist experienced in adverse drug reactions is recommended if desensitization is under consideration. Precautions regarding desensitization include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desensitization is performed immediately before required treatment because maintaining tolerance requires continual exposure to the drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other concurrent health issues should be as well controlled as possible, particularly cardiopulmonary conditions (eg, heart failure, asthma).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should optimally
         <strong>
          not
         </strong>
         be taking medications that may increase the likelihood of anaphylaxis or interfere with treatment of anaphylaxis, such as angiotensin-converting enzyme inhibitors or beta blockers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desensitizations should be performed in an appropriate medical setting, with proper monitoring and immediate availability of rescue medications and equipment. Desensitizations for IgE-mediated sensitivities to intravenous medications are usually performed in an intensive care unit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Documentation of informed consent, including a thorough discussion of risks and benefits of the procedure, is essential.
        </p>
        <p>
        </p>
        <p>
         The safety of desensitization as a general technique is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions", section on 'Safety'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of intravenous protocols have been published. Most can be completed over several hours, which is important for patients who are infected and acutely in need of treatment [
         <a href="#rid24">
          24,43,47-49
         </a>
         ]. Other protocols involve intermittent doses that increase incrementally over periods ranging from 2 to 13 days [
         <a href="#rid27">
          27,37
         </a>
         ]. Studies comparing the success rates of different protocols have not been performed.
        </p>
        <p>
         A protocol that can be completed in several hours is provided  (
         <a class="graphic graphic_table graphicRef59149" href="/z/d/graphic/59149.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Symptoms during desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms during desensitization have been noted in as many as 30 percent of cases and are usually mild (eg, flushing, pruritus, limited urticaria). Most symptoms can be managed without discontinuation of the desensitization protocol. Mild symptoms are managed by halting the infusion and treating the symptoms that do not subside spontaneously. Once symptoms have subsided, the last tolerated step is repeated. This "stepping back" may be performed again if needed, or an intermediate step can be inserted after the last tolerated step and before the problematic step by reducing the infusion rate of the problematic step.
        </p>
        <p>
         If moderate or severe symptoms develop, the infusion should be halted and the symptoms treated. The decision to proceed with desensitization depends upon the patient's status and need for
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         .
        </p>
        <p>
         There is one report of a patient who failed a rapid protocol and was subsequently successfully desensitized using a 13-day procedure [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Duration of effect
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desensitization induces a temporary state of tolerance, allowing the drug to be administered safely as long as the patient remains continually exposed to it. Once the initial desensitization is complete, the patient can receive subsequent doses normally, and no symptoms are anticipated. However, serum levels of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         must be monitored carefully to ensure that the concentration in the blood does not drop below detectable levels [
         <a href="#rid28">
          28,50
         </a>
         ]. It is not known what threshold level of drug is required to maintain the tolerized state. However, the drug levels should be kept within the therapeutic range if possible, both to maintain tolerance and treat the infection. This may require continuous, rather than intermittent, dose infusions.
        </p>
        <p>
         If the drug level becomes undetectable, then desensitization should be repeated in order to reintroduce the medication safely. Once the course of treatment is completed, it must be clearly explained to patients that they still have an allergy to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and would have to be desensitized again if it were required in the future.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          OTHER FORMS OF HYPERSENSITIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common hypersensitivity reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is skin rash. Other reactions, not all of which are immune mediated, include hematologic and kidney disorders, drug fever, and phlebitis [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          DRESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         has elicited drug reaction with eosinophilia and systemic symptoms (DRESS), which is also called drug-induced hypersensitivity syndrome [
         <a href="#rid45">
          45,53-55
         </a>
         ]. This drug reaction involves rash, atypical lymphocytosis, frequent but not uniform eosinophilia, and, often, lymphadenopathy. There may be hepatic, kidney, and/or pulmonary involvement. Treatment involves discontinuing the causative drug and, conventionally, administration of glucocorticoids [
         <a href="#rid46">
          46,54
         </a>
         ]. Amongst an extensive review of electronic medical records of patients developing DRESS, antibiotics accounted for 74 percent, with vancomycin the most common antibiotic (39 percent) overall [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
         Expression of the HLA-A*32:01 allele was found in 83 percent of 23 cases of vancomycin-elicited DRESS versus 0 percent in vancomycin-tolerant control subjects [
         <a href="#rid57">
          57
         </a>
         ]. The authors suggest that, while administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         often needs to be initiated rapidly, since DRESS will not develop usually until after two weeks of drug administration, testing for the HLA-A*32:01 allele be performed soon after initiation of the drug to assess genetic risks for DRESS development. Any drug culprit in DRESS should be avoided in the future as rechallenge can precipitate severe and fatal reactions.
        </p>
        <p class="headingAnchor" id="H2323449">
         <span class="h2">
          Dermatologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common form of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         hypersensitivity reaction is skin rash. Other dermatologic reactions include linear IgA bullous dermatosis (LABD) and various other rare disorders.
        </p>
        <p class="headingAnchor" id="H1588752">
         <span class="h3">
          Maculopapular and urticarial eruptions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maculopapular skin eruptions are the most frequent dermatologic manifestations of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         hypersensitivity [
         <a href="#rid58">
          58-62
         </a>
         ]. In a systematic review of patients receiving teicoplanin or vancomycin, skin rashes occurred in 57 of 889 (6 percent), while vancomycin infusion reaction (VIR) occurred in 18 of 414 (4 percent) [
         <a href="#rid62">
          62
         </a>
         ]. Urticarial eruptions are also reported [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Vancomycin-related linear IgA bullous dermatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         LABD is an autoantibody-mediated skin reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_picture graphicRef77601" href="/z/d/graphic/77601.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid63">
          63-69
         </a>
         ]. In a review of immune-mediated reactions to vancomycin, LABD was the most commonly identified immune-mediated adverse reaction [
         <a href="#rid36">
          36
         </a>
         ]. This entity may be confused with toxic epidermal necrolysis, although LABD does not usually involve mucosal membranes [
         <a href="#rid70">
          70-72
         </a>
         ]. In addition, a nonbullous, morbilliform variant of vancomycin-induced LABD has been reported [
         <a href="#rid73">
          73
         </a>
         ]. LABD can appear from one day to one month from the time of initial vancomycin administration. The reaction appears to be idiosyncratic and unrelated to peak or trough serum vancomycin levels. LABD is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">
          "Linear IgA bullous dermatosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Rare severe cutaneous reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stevens-Johnson syndrome [
         <a href="#rid74">
          74,75
         </a>
         ], exfoliative dermatitis [
         <a href="#rid76">
          76
         </a>
         ], toxic epidermal necrolysis [
         <a href="#rid77">
          77
         </a>
         ], extensive fixed drug eruption [
         <a href="#rid78">
          78
         </a>
         ], and leukocytoclastic vasculitis [
         <a href="#rid79">
          79
         </a>
         ] have all been described in association with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         use in case reports. Early recognition and discontinuation of the drug are critical. Desensitization has no efficacy in these reactions and should not be performed for the purposes of circumventing recurrence, as reexposure to the drug could result in a more severe or fatal recurrence of the reaction. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Hematologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic manifestations of vancomycin-related reactions include leukocytosis, eosinophilia, neutropenia, and immune thrombocytopenia [
         <a href="#rid59">
          59,80-85
         </a>
         ]. Neutropenia tends to occur with longer courses of therapy, and weekly monitoring of the white blood cell count and differential leukocyte counts during prolonged administration is indicated [
         <a href="#rid86">
          86
         </a>
         ]. A case of agranulocytosis in a patient with kidney insufficiency was also reported [
         <a href="#rid18">
          18
         </a>
         ].
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         should be discontinued if these conditions develop.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Drug-induced fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncommonly,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         has been implicated as a cause of drug-induced fever [
         <a href="#rid51">
          51,52,87
         </a>
         ]. In some instances, fever has occurred concomitant with vancomycin-elicited neutropenia [
         <a href="#rid58">
          58,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Kidney
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         may cause nephrotoxicity, especially in patients receiving confounding nephrotoxins or who have kidney insufficiency or altered hemodynamics [
         <a href="#rid88">
          88-90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/484.html" rel="external">
          "Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"
         </a>
         .)
        </p>
        <p>
         On occasion,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         can also elicit immunologically mediated kidney damage due to acute interstitial nephritis [
         <a href="#rid91">
          91-93
         </a>
         ]. Vancomycin should be discontinued if it is a likely cause of acute interstitial nephritis. (See
         <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">
          "Clinical manifestations and diagnosis of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          USE OF RELATED DRUGS
         </span>
        </p>
        <p class="headingAnchor" id="H3346649183">
         <span class="h2">
          Glycopeptide antibiotic analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The agents that share structural similarities with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         include teicoplanin,
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         ,
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">
          telavancin
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ]. Teicoplanin has been in use longer than the other agents, so there is more experience with the adverse reactions it can cause.
        </p>
        <p class="headingAnchor" id="H1699743822">
         <span class="h3">
          Teicoplanin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Teicoplanin, which is not available in the United States, is a glycopeptide antimicrobial with structural similarity to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , equivalent efficacy in treating invasive beta-lactam-resistant, gram-positive infections, but with apparently lower rates of adverse events, particularly nephrotoxicity and vancomycin infusion reaction (VIR) [
         <a href="#rid62">
          62,94-96
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Teicoplanin can cause flushing and pruritus, but clinically significant infusion reactions are rare with teicoplanin [
         <a href="#rid94">
          94,97,98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Teicoplanin has been implicated in perioperative anaphylaxis [
         <a href="#rid99">
          99-101
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There is only limited information about the safety of teicoplanin in patients with a previous hypersensitivity reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrence of vasculitic rash was described in two patients treated with teicoplanin who had previously reacted to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective series evaluated 117 patients who had drug-induced fever (24 patients), rash (77 patients), both (8 patients), or neutropenia (8 patients) while receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and were switched to teicoplanin [
         <a href="#rid58">
          58
         </a>
         ]. Clinical information and the development of drug-induced fever, rash, or neutropenia with teicoplanin were determined by medical record review. Ten percent of patients developed fever, rash, or neutropenia in response to teicoplanin; there were no fatalities due to drug adverse reactions to teicoplanin. Of note, 50 percent of patients with neutropenia in response to vancomycin also developed neutropenia in response to teicoplanin. Thus, the majority of patients in the series tolerated teicoplanin, with the exception of those with neutropenia, in whom one-half had recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Teicoplanin can induce drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome, like
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid45">
          45,53
         </a>
         ]. Cross-sensitivity to both drugs is possible, as described in at least one case report [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4090164694">
         <span class="h3">
          Dalbavancin, oritavancin, and telavancin
         </span>
         <span class="headingEndMark">
          —
         </span>
         These analogs of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         are approved for use in the United States, including for skin and skin structure infections [
         <a href="#rid42">
          42
         </a>
         ].
         <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">
          Telavancin
         </a>
         is administered daily, while
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         and
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         are long lived and are usually given as a single dose. While the long-lasting antimicrobial effects of these agents are beneficial, adverse reactions to these agents may produce persistent symptoms that extend well beyond discontinuation of the drug.
        </p>
        <p>
         Reports of adverse effects from these agents are limited but appear to be less common than with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VIR-like reactions have been reported with both
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         and
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         and can be managed with slower infusion rates [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaphylaxis has also been reported with both agents, but details that might distinguish IgE-mediated anaphylaxis from nonimmune-mediated pseudoallergic reactions are not available [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Reports of adverse reactions to
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         and
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         in patients with previous serious adverse reactions to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         are also limited, and we would advise exploring other options before using related glycopeptide agents. Specifically, alternative antibiotics should be utilized when possible. If the concern is about a VIR-like infusion-related event, appropriate precautions should be taken (slower infusion rate, consideration of relevant coadministered medications)  (
         <a class="graphic graphic_table graphicRef74197" href="/z/d/graphic/74197.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Graded challenge has be performed in a controlled setting to ascertain if a patient with a previous immediate hypersensitivity reaction to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         could tolerate one of the newer glycopeptide agents. One case report described a graded challenge of
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         in a patient with a past severe hypersensitivity reaction to vancomycin [
         <a href="#rid105">
          105
         </a>
         ]. However, the patient was also receiving opioids and had other conditions that could have potentiated the reaction to vancomycin, so the safety of this approach in other patients with severe hypersensitivity is unclear.
        </p>
        <p class="headingAnchor" id="H2203738502">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">
          "Society guideline links: Drug allergy and hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         <strong>
          and clinical manifestations
         </strong>
         –
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         infusion reaction (VIR; also known as "red man syndrome," though we avoid the use of this term going forward) is a common adverse reaction to vancomycin. VIR is characterized by flushing, erythema, and pruritus, usually of the upper body. Chest or back pains and hypotension may also occur. It is a rate-related infusion reaction caused by direct activation of mast cells by the drug. Other agents that activate mast cells, such as opioids, muscle relaxants, and radiocontrast media, can predispose patients to developing VIR with vancomycin infusion. (See
         <a class="local">
          'Vancomycin infusion reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Slower infusion rates can prevent VIR
         </strong>
         – VIR can usually be prevented by administering the drug at rates ≤10 mg/minute (or 1 gram over more than 100 minutes). We do not empirically premedicate patients who have no history of previous VIR or have never received
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         before if the drug is to be administered at these rates. (See
         <a class="local">
          'Prevention of initial reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premedication for patients who require faster infusions
         </strong>
         – In patients who require more rapid infusions of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (ie, at rates exceeding 10 mg/minute or 1 gram over one hour), we recommend antihistamine premedication with at least an H1 antihistamine (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest a combination of H1 and H2 antihistamines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We administer the combination of
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally) and
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         (20 mg orally) one hour before infusion, although the optimal regimen has not been determined. (See
         <a class="local">
          'Prevention of initial reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of VIR
         </strong>
         – VIR is treated by stopping the infusion. Further treatment depends upon the severity of the reaction. The patient's medication list should be reviewed carefully to determine if other predisposing medications can be identified and discontinued  (
         <a class="graphic graphic_table graphicRef74197" href="/z/d/graphic/74197.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For mild reactions (eg, flushing that is not bothersome to the patient), symptoms typically resolve in minutes, and antihistamines are usually not necessary. We usually restart the infusion at one-half of the previous rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For moderate reactions (eg, the patient is uncomfortable due to flushing or pruritus but is hemodynamically stable and not experiencing chest pain or muscle spasm), we suggest treating with an H1 antihistamine (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We administer
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally or intravenously). We usually restart the infusion at one-half of the previous rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For severe reactions (eg, muscle spasms, chest pain, or hypotension), in addition to stopping the infusion, we suggest treatment with both H1 and H2 antihistamines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We administer
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg intravenously) and
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         (20 mg intravenously). Intravenous fluids may be needed for hypotension. We suggest infusing any subsequent doses of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         over four hours with continuous hemodynamic monitoring during infusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of repeat reactions
         </strong>
         – For patients with a previous history of VIR who require
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         again, we recommend antihistamine premedication with at least an H1 antihistamine (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest a combination of H1 and H2 antihistamines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We administer the combination of
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         (50 mg orally) and
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         (20 mg orally) one hour before infusion and infuse each vancomycin dose over four hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for desensitization
         </strong>
         – For patients with recurrent VIR despite premedication and slow infusion rates who absolutely require
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         in the future, we suggest desensitization (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Desensitization involves gradually reintroducing the culprit drug in serially increasing doses to induce a state of temporary clinical tolerance. There are several published protocols. We prefer a rapid protocol that allows the patient to receive a full dose of vancomycin within several hours  (
         <a class="graphic graphic_table graphicRef59149" href="/z/d/graphic/59149.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Desensitization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rare anaphylaxis
         </strong>
         – Anaphylaxis in response to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         administration is rare. Symptoms of anaphylaxis overlap with those of severe VIR, although wheezing, significant dyspnea, and angioedema are more suggestive of anaphylaxis  (
         <a class="graphic graphic_table graphicRef66333" href="/z/d/graphic/66333.html" rel="external">
          table 4
         </a>
         ). Multiple prior vancomycin courses should raise concern about the potential for immunoglobulin E (IgE) mediated anaphylaxis. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – For patients with anaphylaxis of any severity:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The infusion should be stopped immediately and not restarted.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          Epinephrine
         </a>
         should be administered promptly, at the doses specified for adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 2
         </a>
         ) or children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Acute management'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment", section on 'Immediate management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Future management options
         </strong>
         – For patients with past anaphylaxis to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , an alternative drug should be used whenever possible. For patients with serious infections that cannot be adequately treated with alternate antibiotics, we suggest vancomycin desensitization (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Desensitization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other rare types of reactions
         </strong>
         – Other rare forms of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         hypersensitivity include drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome, linear immunoglobulin A (IgA) bullous dermatosis (LABD)  (
         <a class="graphic graphic_picture graphicRef77601" href="/z/d/graphic/77601.html" rel="external">
          picture 1
         </a>
         ), and immune-mediated hematologic and kidney disorders. The drug must be discontinued if these occur. Desensitization in patients with these reactions is not effective and may be dangerous. (See
         <a class="local">
          'Other forms of hypersensitivity'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Austin JP, Foster BA, Empey A. Replace Red Man Syndrome With Vancomycin Flushing Reaction. Hosp Pediatr 2020; 10:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Arango S, Ogunwole SM, Sequist TD, et al. Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome". N Engl J Med 2021; 384:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagahama Y, VanBeek MJ, Greenlee JDW. Red man syndrome caused by vancomycin powder. J Clin Neurosci 2018; 50:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao S, Kupfer Y, Pagala M, et al. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis 2011; 43:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother 1994; 28:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symons NL, Hobbes AF, Leaver HK. Anaphylactoid reactions to vancomycin during anaesthesia: two clinical reports. Can Anaesth Soc J 1985; 32:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg 2003; 97:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glicklich D, Figura I. Vancomycin and cardiac arrest. Ann Intern Med 1984; 101:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hicks RW, Hernandez J. Perioperative pharmacology: a focus on vancomycin. AORN J 2011; 93:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foer D, Wien M, Karlson EW, et al. Patient Characteristics Associated With Reactions to Mrgprx2-Activating Drugs in an Electronic Health Record-Linked Biobank. J Allergy Clin Immunol Pract 2023; 11:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayhew JF, Deutsch S. Cardiac arrest following administration of vancomycin. Can Anaesth Soc J 1985; 32:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veien M, Szlam F, Holden JT, et al. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000; 92:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horinouchi Y, Abe K, Kubo K, Oka M. Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells. Agents Actions 1993; 40:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015; 519:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, et al. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep 2018; 8:11628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 1990; 34:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace MR, Mascola JR, Oldfield EC 3rd. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 1991; 164:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrouny A, Meguerditchian S, Koo CH, et al. Agranulocytosis related to vancomycin therapy. Am J Med 1986; 81:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Sullivan TL, Ruffing MJ, Lamp KC, et al. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis 1993; 168:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renz CL, Thurn JD, Finn HA, et al. Oral antihistamines reduce the side effects from rapid vancomycin infusion. Anesth Analg 1998; 87:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newfield P, Roizen MF. Hazards of rapid administration of vancomycin. Ann Intern Med 1979; 91:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polk RE, Healy DP, Schwartz LB, et al. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 1988; 157:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Marty AT. Vancomycin and adverse drug reactions. Crit Care Med 1993; 21:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong JT, Ripple RE, MacLean JA, et al. Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol. J Allergy Clin Immunol 1994; 94:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renz CL, Thurn JD, Finn HA, et al. Antihistamine prophylaxis permits rapid vancomycin infusion. Crit Care Med 1999; 27:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassaballa H, Mallick N, Orlowski J. Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome. Am J Ther 2000; 7:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anne' S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994; 73:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chopra N, Oppenheimer J, Derimanov GS, Fine PL. Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels. Ann Allergy Asthma Immunol 2000; 84:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998; 80:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renz CL, Laroche D, Thurn JD, et al. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology 1998; 89:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laroche D, Vergnaud MC, Sillard B, et al. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology 1991; 75:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz LB, Yunginger JW, Miller J, et al. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsson P, Enander I, Andersson AS, et al. Evaluation of mast cell activation (tryptase) in two patients suffering from drug-induced hypotensoid reactions. Agents Actions 1991; 33:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordoqui E, Zubeldia JM, Aranzábal A, et al. Serum tryptase levels in adverse drug reactions. Allergy 1997; 52:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minhas JS, Wickner PG, Long AA, et al. Immune-mediated reactions to vancomycin: A systematic case review and analysis. Ann Allergy Asthma Immunol 2016; 116:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin RY. Desensitization in the management of vancomycin hypersensitivity. Arch Intern Med 1990; 150:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perencevich EN, Weller PF, Samore MH, Harris AD. Benefits of negative penicillin skin test results persist during subsequent hospital admissions. Clin Infect Dis 2001; 32:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigas E, Park MA, Narr BJ, et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clin Proc 2008; 83:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006; 97:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilmore JF, Kim M, LaSalvia MT, Mahoney MV. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. Perit Dial Int 2013; 33:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaskovich MAT, Hansford KA, Butler MS, et al. Developments in Glycopeptide Antibiotics. ACS Infect Dis 2018; 4:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villavicencio AT, Hey LA, Patel D, Bressler P. Acute cardiac and pulmonary arrest after infusion of vancomycin with subsequent desensitization. J Allergy Clin Immunol 1997; 100:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitazawa T, Ota Y, Kada N, et al. Successful vancomycin desensitization with a combination of rapid and slow infusion methods. Intern Med 2006; 45:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon HS, Chang YS, Jeong YY, et al. A case of hypersensitivity syndrome to both vancomycin and teicoplanin. J Korean Med Sci 2006; 21:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother 2001; 35:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerner A, Dwyer JM. Desensitization to vancomycin. Ann Intern Med 1984; 100:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen SJ, Wise SL, al-Tawfiq JA, et al. Successful vancomycin desensitization in a patient with end-stage renal disease and anaphylactic shock to vancomycin. Ann Pharmacother 1998; 32:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayman MD, Capaldo RA. Vancomycin allergy presenting as fever of unknown origin. Arch Intern Med 1989; 149:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha JL, Kondo W, Baptista MI, et al. Uncommon vancomycin-induced side effects. Braz J Infect Dis 2002; 6:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamagawa-Mineoka R, Katoh N, Nara T, et al. DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6. Int J Dermatol 2007; 46:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauthey L, Uçkay I, Abrassart S, et al. Vancomycin-induced DRESS syndrome in a female patient. Pharmacology 2008; 82:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boet S, Noblet C, Haas-Hubscher C, et al. Severe vancomycin-induced drug rash with eosinophilia and systemic symptoms syndrome imitating septic shock. Eur J Anaesthesiol 2009; 26:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfson AR, Zhou L, Li Y, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. J Allergy Clin Immunol Pract 2019; 7:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol 2019; 144:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung YP, Lee NY, Chang CM, et al. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review. Clin Ther 2009; 31:1977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           An SY, Hwang EK, Kim JH, et al. Vancomycin-associated spontaneous cutaneous adverse drug reactions. Allergy Asthma Immunol Res 2011; 3:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrin-Lamarre A, Petitpain N, Trechot P, et al. [Glycopeptide-induced cutaneous adverse reaction: results of an immunoallergic investigation in eight patients]. Ann Dermatol Venereol 2010; 137:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prey S, Sparsa A, Boumediene A, et al. [Cutaneous drug reactions induced by glycopeptides]. Med Mal Infect 2007; 37:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Costarangos C, Anhalt GJ. Vancomycin-associated linear IgA bullous dermatosis. Ann Intern Med 1998; 129:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein EF, Schuster M. Linear IgA bullous dermatosis associated with vancomycin. Ann Intern Med 1998; 129:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitman LM, Grossman ME, Ross H. Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease. Arch Dermatol 1996; 132:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards SS, Hall S, Yokel B, Whitmore SE. A bullous eruption in an elderly woman. Vancomycin-associated linear IgA dermatosis (LAD). Arch Dermatol 1995; 131:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neughebauer BI, Negron G, Pelton S, et al. Bullous skin disease: an unusual allergic reaction to vancomycin. Am J Med Sci 2002; 323:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solky BA, Pincus L, Horan RF. Vancomycin-induced linear IgA bullous dermatosis: morphology is a key to diagnosis. Cutis 2004; 73:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onodera H, Mihm MC Jr, Yoshida A, Akasaka T. Drug-induced linear IgA bullous dermatosis. J Dermatol 2005; 32:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mofid MZ, Costarangos C, Bernstein B, et al. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coelho S, Tellechea O, Reis JP, et al. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol 2006; 45:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JS, Hamilton CD, Patel S, et al. Linear Immunoglobulin A (IgA) Bullous Dermatosis Mimicking Stevens-Johnson Syndrome. Cureus 2022; 14:e30309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billet SE, Kortuem KR, Gibson LE, El-Azhary R. A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol 2008; 144:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurencin CT, Horan RF, Senatus PB, et al. Stevens-Johnson-type reaction with vancomycin treatment. Ann Pharmacother 1992; 26:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander II, Greenberger PA. Vancomycin-induced Stevens-Johnson syndrome. Allergy Asthma Proc 1996; 17:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal D, Morton R, Bailie GR, Waldek S. Exfoliative reaction to vancomycin. Br Med J (Clin Res Ed) 1988; 296:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidal C, González Quintela A, Fuente R. Toxic epidermal necrolysis due to vancomycin. Ann Allergy 1992; 68:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilmore ES, Friedman JS, Morrell DS. Extensive fixed drug eruption secondary to vancomycin. Pediatr Dermatol 2004; 21:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felix-Getzik E, Sylvia LM. Vancomycin-induced leukocytoclastic vasculitis. Pharmacotherapy 2009; 29:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Pharmacotherapy 1997; 17:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PF, Taylor CT. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacotherapy 1999; 19:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christie DJ, van Buren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990; 75:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marraffa J, Guharoy R, Duggan D, et al. Vancomycin-induced thrombocytopenia: a case proven with rechallenge. Pharmacotherapy 2003; 23:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis AG, Grisi SJ. Adverse effects of vancomycin in children: a review of 22 cases. Sao Paulo Med J 1997; 115:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011; 45:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labbus K, Junkmann JK, Perka C, et al. Antibiotic-induced fever in orthopaedic patients-a diagnostic challenge. Int Orthop 2018; 42:1775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010; 123:182.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010; 77:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welch HK, Kellum JA, Kane-Gill SL. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmacotherapy 2018; 38:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wai AO, Lo AM, Abdo A, Marra F. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother 1998; 32:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salazar MN, Matthews M, Posadas A, et al. Biopsy proven interstitial nephritis following treatment with vancomycin: a case report. Conn Med 2010; 74:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Codding CE, Ramseyer L, Allon M, et al. Tubulointerstitial nephritis due to vancomycin. Am J Kidney Dis 1989; 14:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother 2000; 12 Suppl 5:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53:4069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998; 10:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khurana C, de Belder MA. Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin. Postgrad Med J 1999; 75:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahai J, Healy DP, Shelton MJ, et al. Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother 1990; 34:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sice PJA, Ford S, Whyte AF, Greig JR. Teicoplanin hypersensitivity during anaesthesia and surgery. Br J Clin Pharmacol 2019; 85:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azamgarhi T, Shah A, Warren S. Teicoplanin anaphylaxis associated with surgical prophylaxis. Br J Clin Pharmacol 2018; 84:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savic LC, Garcez T, Hopkins PM, et al. Teicoplanin allergy - an emerging problem in the anaesthetic allergy clinic. Br J Anaesth 2015; 115:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall C, Street A, Galbraith K. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin. J Infect 1998; 37:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henson KE, Levine MT, Wong EA, Levine DP. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. Expert Rev Anti Infect Ther 2015; 13:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn AW, Jain R, Spach DH. New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents. Med Clin North Am 2016; 100:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishizuka KT, Tran TK, Ayars AG, et al. Graded Dalbavancin Challenge in a Patient With Severe Vancomycin Hypersensitivity Reaction. Clin Infect Dis 2020; 70:1230.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2083 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32571794" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Replace Red Man Syndrome With Vancomycin Flushing Reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33830710" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29398192" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Red man syndrome caused by vancomycin powder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21198337" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Systemic absorption of oral vancomycin in patients with Clostridium difficile infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8068993" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3986655" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Anaphylactoid reactions to vancomycin during anaesthesia: two clinical reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14570656" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Anaphylaxis during the perioperative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6497209" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Vancomycin and cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21530708" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Perioperative pharmacology: a focus on vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36356925" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Patient Characteristics Associated With Reactions to Mrgprx2-Activating Drugs in an Electronic Health Record-Linked Biobank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3971208" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cardiac arrest following administration of vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10754628" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7511870" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25517090" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072729" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1693055" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1955716" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Red man syndrome: incidence, etiology, and prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3799634" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Agranulocytosis related to vancomycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8354921" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prospective evaluation of red man syndrome in patients receiving vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9728853" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Oral antihistamines reduce the side effects from rapid vancomycin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/484963" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hazards of rapid administration of vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2449506" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Vancomycin and the red-man syndrome: pharmacodynamics of histamine release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7687945" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Vancomycin and adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7914900" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10507591" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Antihistamine prophylaxis permits rapid vancomycin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11317179" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7978531" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Vancomycin anaphylaxis and successful desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10875494" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9505773" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mast cell tryptase in anaesthetic anaphylactoid reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743397" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1741515" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2468689" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1897443" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Evaluation of mast cell activation (tryptase) in two patients suffering from drug-induced hypotensoid reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9404562" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum tryptase levels in adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7929694" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27156746" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Immune-mediated reactions to vancomycin: A systematic case review and analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2222107" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Desensitization in the management of vancomycin hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11170927" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Benefits of negative penicillin skin test results persist during subsequent hospital admissions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18533082" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17165279" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23843587" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29363950" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Developments in Glycopeptide Antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9438500" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute cardiac and pulmonary arrest after infusion of vancomycin with subsequent desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16596002" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Successful vancomycin desensitization with a combination of rapid and slow infusion methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179696" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A case of hypersensitivity syndrome to both vancomycin and teicoplanin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19440116" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11724099" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Desensitization protocols for vancomycin hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6691643" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Desensitization to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17088655" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Desensitization for drug allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9793593" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Successful vancomycin desensitization in a patient with end-stage renal disease and anaphylactic shock to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2730262" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Vancomycin allergy presenting as fever of unknown origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204187" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Uncommon vancomycin-induced side effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17550572" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18607115" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Vancomycin-induced DRESS syndrome in a female patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19424074" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Severe vancomycin-induced drug rash with eosinophilia and systemic symptoms syndrome imitating septic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30176295" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30776417" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19843487" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21738885" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vancomycin-associated spontaneous cutaneous adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171430" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : [Glycopeptide-induced cutaneous adverse reaction: results of an immunoallergic investigation in eight patients].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17434698" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : [Cutaneous drug reactions induced by glycopeptides].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20556772" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Teicoplanin versus vancomycin for proven or suspected infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735094" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Vancomycin-associated linear IgA bullous dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735095" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Linear IgA bullous dermatosis associated with vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915304" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492136" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A bullous eruption in an elderly woman. Vancomycin-associated linear IgA dermatosis (LAD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12018672" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Bullous skin disease: an unusual allergic reaction to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14964634" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Vancomycin-induced linear IgA bullous dermatosis: morphology is a key to diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16361722" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Drug-induced linear IgA bullous dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10850906" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16911399" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36381872" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Linear Immunoglobulin A (IgA) Bullous Dermatosis Mimicking Stevens-Johnson Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559768" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1482807" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Stevens-Johnson-type reaction with vancomycin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8934797" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Vancomycin-induced Stevens-Johnson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2962694" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Exfoliative reaction to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1558331" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Toxic epidermal necrolysis due to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15461771" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Extensive fixed drug eruption secondary to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558258" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Vancomycin-induced leukocytoclastic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399623" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Delayed hypersensitivity reaction to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030777" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17329697" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Vancomycin-induced immune thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2295006" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14524652" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Vancomycin-induced thrombocytopenia: a case proven with rechallenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9532849" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Adverse effects of vancomycin in children: a review of 22 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21521866" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Vancomycin-induced neutropenia: is it dose- or duration-related?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29600426" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Antibiotic-induced fever in orthopaedic patients-a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20103028" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182415" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Recent changes in vancomycin use in renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29883524" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9825081" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Vancomycin-induced acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20391819" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Biopsy proven interstitial nephritis following treatment with vancomycin: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2596477" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Tubulointerstitial nephritis due to vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11131960" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Comparative safety of teicoplanin and vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19596875" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9716291" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Comparative safety of teicoplanin and vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10396588" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1694421" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30421516" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Teicoplanin hypersensitivity during anaesthesia and surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29319891" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Teicoplanin anaphylaxis associated with surgical prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26385667" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Teicoplanin allergy - an emerging problem in the anaesthetic allergy clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9733391" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26165756" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27235621" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31300814" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Graded Dalbavancin Challenge in a Patient With Severe Vancomycin Hypersensitivity Reaction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
